Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that has efficacy in recurrent malignant gliomas, particularly in combination with irinotecan. However, responses are rarely durable. Continuation of bevacizumab in combination with another chemotherapeu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Quant, Eudocia C., Norden, Andrew D., Drappatz, Jan, Muzikansky, Alona, Doherty, Lisa, LaFrankie, Debra, Ciampa, Abigail, Kesari, Santosh, Wen, Patrick Y.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Duke University Press 2009
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2765344/
https://ncbi.nlm.nih.gov/pubmed/19332770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2009-006
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller